Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

  1. Girard, N.
  2. Bar, J.
  3. Garrido, P.
  4. Garassino, M.C.
  5. McDonald, F.
  6. Mornex, F.
  7. Filippi, A.R.
  8. Smit, H.J.M.
  9. Peters, S.
  10. Field, J.K.
  11. Christoph, D.C.
  12. Sibille, A.
  13. Fietkau, R.
  14. Haakensen, V.D.
  15. Chouaid, C.
  16. Markman, B.
  17. Hiltermann, T.J.N.
  18. Taus, A.
  19. Sawyer, W.
  20. Allen, A.
  21. Chander, P.
  22. Licour, M.
  23. Solomon, B.
Revista:
Journal of Thoracic Oncology

ISSN: 1556-1380,  1556-0864

Any de publicació: 2023

Volum: 18

Número: 2

Pàgines: 181-193

Tipus: Article

DOI: 10.1016/J.JTHO.2022.10.003 GOOGLE SCHOLAR lock_openAccés obert editor

Objectius de Desenvolupament Sostenible

Font de les dades: Scopus